A carregar...
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
Twenty-one percent of all human cancers bear constitutively activating mutations in the proto-oncogene KRAS. This incidence is substantially higher in some of the most inherently therapy-resistant cancers including 30% of non-small cell lung cancers (NSCLC), 50% of colorectal cancers, and 95% of pan...
Na minha lista:
| Publicado no: | Cell Death Discov |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7078304/ https://ncbi.nlm.nih.gov/pubmed/32194994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41420-020-0249-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|